Not Yet RecruitingPhase 2

Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections

Pakistan120 participantsStarted 2024-11-15

Plain-language summary

Treatment of dermatophyte infection in our country (Pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness ,feasibility and standard dosage of a newer antifungal drug like voriconazole is the need of the hour in resistant cases of dermatophyte infection.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Resistant cases of tinea cruris and tinea corporis: Those cases who received the standard dosage of oral antifungals i.e. oral terbinafine 5mg/kg per day for 4 weeks or oral itraconazole 5mg per/kg/day for 4 weeks but they did not recover from the infection.
✓. Skin area: Groin and trunk
✓. Total diameter of the lesions: 5cm to 80 cm

Exclusion criteria

✕. History of hypersensitivity to azoles
✕. All those individuals having immunocompromised state (malignancy, tuberculosis, AIDS, history of organ transplant and history of immunosuppressive drug treatment etc.)
✕. Patients of diabetes, liver or kidney disease.
✕. Lactating mother
✕. Pregnant female

What they're measuring

Efficacy of oral voriconazole 200 mg once daily(low dose) vs. twice daily (high dose)

Timeframe: Clinical assessment for efficacy will be done at day 14 and day 28

Trial details

NCT IDNCT06680544

SponsorSheikh Zayed Medical College

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-03-01

Contact for this trial

Muhammad Khurram Shahzad, FCPS dermatology

+923354847957 dr.khuram178@gmail.com

View on ClinicalTrials.gov More Dermatophyte Infection trials